STAAR Surgical (STAA) Stock Forecast & Price Target

Staar Surgical Co is positioned favorably within the rapidly expanding ophthalmic surgical and diagnostic devices market, which is projected to reach $20.1 billion by 2025, reflecting a compound annual growth rate of 2.9% since 2019. The company's Implantable Collamer lenses (ICL) have significantly increased their market share from 14.3% in 2019 to an estimated 26.5% in 2025, demonstrating robust demand against a backdrop of growing alternatives such as corneal-based laser procedures. Furthermore, recent developments, including an increased acquisition bid from Alcon, signal strong investor confidence and underline the company's positive recovery trajectory and competitive positioning in the eye care market.

Staar Surgical Co. is facing significant financial challenges, primarily driven by severe revenue declines resulting from an unprecedented collapse in its China operations, where revenue fell by as much as 99% year-over-year in early 2025. The company is also experiencing EBITDA losses and ongoing cash consumption, alongside strategic uncertainty that undermines its ability to achieve the sustained growth necessary for premium valuation. Compounding these issues, Staar's stock trades at a substantial discount to historical multiples, with risks that market sentiment may remain bearish until the company demonstrates consistent performance amidst increased competition and shifting consumer preferences.